Abbott Laboratories’ (ABT) “Buy” Rating Reiterated at TD Cowen

Abbott Laboratories (NYSE:ABT)‘s stock had its “buy” rating reissued by TD Cowen in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $115.00 price target on the healthcare product maker’s stock. TD Cowen’s price objective points to a potential upside of 14.04% from the stock’s previous close.

Several other research analysts have also recently weighed in on the stock. Royal Bank Of Canada reiterated an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a report on Friday. Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research note on Wednesday, April 22nd. Stifel Nicolaus reduced their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. The Goldman Sachs Group decreased their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $117.74.

Abbott Laboratories Trading Up 2.0%

Shares of ABT stock traded up $2.01 on Friday, reaching $100.84. 3,101,885 shares of the stock were exchanged, compared to its average volume of 12,278,043. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock has a market cap of $175.65 billion, a PE ratio of 28.30, a P/E/G ratio of 1.54 and a beta of 0.61. The stock has a 50 day moving average price of $89.56 and a 200 day moving average price of $102.18. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip P. Boudreau bought 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors have recently made changes to their positions in the stock. Radnor Capital Management LLC lifted its holdings in shares of Abbott Laboratories by 4.3% in the 2nd quarter. Radnor Capital Management LLC now owns 19,792 shares of the healthcare product maker’s stock worth $1,796,000 after acquiring an additional 807 shares during the last quarter. Activest Wealth Management raised its stake in shares of Abbott Laboratories by 91.9% in the second quarter. Activest Wealth Management now owns 856 shares of the healthcare product maker’s stock worth $78,000 after purchasing an additional 410 shares during the last quarter. Brown Miller Wealth Management LLC boosted its holdings in Abbott Laboratories by 0.9% in the second quarter. Brown Miller Wealth Management LLC now owns 41,809 shares of the healthcare product maker’s stock worth $3,794,000 after purchasing an additional 370 shares during the last quarter. Simplify Asset Management Inc. boosted its position in Abbott Laboratories by 32.5% in the second quarter. Simplify Asset Management Inc. now owns 20,546 shares of the healthcare product maker’s stock worth $1,864,000 after purchasing an additional 5,040 shares during the last quarter. Finally, Capital Advisors Ltd. LLC lifted its stake in shares of Abbott Laboratories by 13.5% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 3,625 shares of the healthcare product maker’s stock worth $329,000 after purchasing an additional 432 shares during the period. Institutional investors own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported Q2 adjusted EPS of $1.31, edging past estimates, while revenue rose 13% year over year to $12.51 billion, signaling broad underlying demand. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: The company lifted its 2026 adjusted EPS guidance to $5.45-$5.60 and kept its comparable sales outlook intact, which investors read as a sign of confidence in second-half momentum. Abbott raises 2026 profit forecast on heart device strength
• Positive Sentiment: Growth in medical devices and diagnostics, especially stronger demand for heart devices, helped offset softer areas and supported the upbeat guidance update. Abbott Stock’s Best Day Ever: +13.6% On Earnings Beat, Guidance Raise
• Positive Sentiment: BTIG Research raised its price target to $134 from $131 and reiterated a Buy rating, implying meaningful upside from current levels and adding to the bullish post-earnings sentiment. Benzinga analyst update
• Neutral Sentiment: Several market commentaries highlighted that ABT had been viewed as undervalued or recovering from a prior decline, but these were mostly opinion pieces rather than new fundamentals. Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall?

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.